CredoScientia - Bibliothèque

Multimodal Management of Colorectal Liver Metastases: State of the Art.

Liver is the most common site of colorectal cancer (CRC) metastases. Treatment of CRC liver metastases (CRLM) includes different strategies, prevalently based on the clinical and oncological intent. V…

Thérapies de Conversion

Filoni, E., Musci, V., Di, R. i. t. o. . A., Inchingolo, R., Memeo, R., & Mannavola, F. (2023). Multimodal Management of Colorectal Liver Metastases: State of the Art.. Oncol Rev, 17, 11799. https://doi.org/10.3389/or.2023.11799

01/01/2023 Lire →

Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.

As stage IIIC non-small cell lung cancer (NSCLC) is not recommended for surgical resection, the survival and prognosis for stage IIIC NSCLC remain poor. More powerful and individualized therapies are …

Thérapies de Conversion

Fu, Y., Duan, W., Xu, R., & Chen, J. (2023). Conversion therapy with immunotherapy plus chemotherapy achieves a pathological complete response in stage IIIC NSCLC.. Front Immunol, 14, 1268153. https://doi.org/10.3389/fimmu.2023.1268153

01/01/2023 Lire →

Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.

BACKGROUND: Currently, gastric cancer with positive lavage cytology without gross peritoneal dissemination (GC-CY1) is a special type of metastatic form with poor prognosis. Consensus guidelines on tr…

Thérapies de Conversion

Lv, J., Wu, J., Wu, H., Ding, P., Guo, H., Yang, P., Tian, Y., Liu, Y., & Zhao, Q. (2023). Study protocol of a phase II clinical trial evaluating the efficacy of neoadjuvant intraperitoneal and systemic albumin-bound paclitaxel combined with camrelizumab and S-1 in the treatment of patients with exfoliative cell-positive gastric cancer.. Front Oncol, 13, 1201928. https://doi.org/10.3389/fonc.2023.1201928

01/01/2023 Lire →

Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy.

Thérapies de Conversion

Zhang, E. L. (2023). Editorial: Immunomodulatory factors, conversion, and postoperative adjuvant therapy for hepatobiliary tumors based on immunotherapy.. Front Immunol, 14, 1218845. https://doi.org/10.3389/fimmu.2023.1218845

01/01/2023 Lire →

Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.

[This corrects the article DOI: 10.3389/fimmu.2023.1151967.].

Thérapies de Conversion

Wang, G., Zhang, W., Luan, X., Wang, Z., Liu, J., Xu, X., Zhang, J., Xu, B., Lu, S., Wang, R., & Ma, G. (2023). Corrigendum: The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.. Front Immunol, 14, 1219757. https://doi.org/10.3389/fimmu.2023.1219757

01/01/2023 Lire →

Hormonal changes resulting from transgender conversion therapy may represent a gap in the biological effects of radiation understanding.

Thérapies de Conversion

Andrade, E. R. (2023). Hormonal changes resulting from transgender conversion therapy may represent a gap in the biological effects of radiation understanding.. Int J Radiat Biol, 99(11), 1800-1801. https://doi.org/10.1080/09553002.2023.2211147

01/01/2023 Lire →

Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma.

BACKGROUND: Most patients with hepatocellular carcinoma (HCC) are not candidates for liver resection. We investigated the clinicopathological characteristics and prognosis of patients with initially u…

Thérapies de Conversion

Yu, B., Zhang, N., Feng, Y., Zhang, Y., Zhang, T., & Wang, L. (2023). Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 10, 1709-1721. https://doi.org/10.2147/JHC.S432062

01/01/2023 Lire →

Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma.

BACKGROUND: Laparoscopic hepatectomy (LH) is more advantageous than open hepatectomy (OH) for hepatocellular carcinoma (HCC). However, surgical methods of conversion resection for patients with HCC ha…

Thérapies de Conversion

Yang, Z., Hu, Z., Fu, Y., Hu, D., Zhou, Z., Chen, M., Pan, Y., & Zhang, Y. (2023). Laparoscopic Hepatectomy versus Open Hepatectomy After Conversion Therapy Using Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy for Patients with Initially Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 10, 1157-1167. https://doi.org/10.2147/JHC.S417739

01/01/2023 Lire →

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.

PURPOSE: The purpose of this study was to investigate the triple-combination therapy of lenvatinib plus sintilimab plus arterially-directed therapy as a conversion therapy for initially unresectable h…

Thérapies de Conversion

Gan, L., Lang, M., Tian, X., Ren, S., Li, G., Liu, Y., Han, R., Zhu, K., Li, H., Wu, Q., Cui, Y., Zhang, W., Fang, F., Li, Q., & Song, T. (2023). A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma.. J Hepatocell Carcinoma, 10, 673-686. https://doi.org/10.2147/JHC.S404675

01/01/2023 Lire →

The Current Status of Sociopolitical and Legal Issues Faced by Lesbian, Gay, Bisexual, Transgender, Queer, and Questioning Youth.

BACKGROUND: Adolescents today have unprecedented and uninterrupted access to news and current events through broadcast and social media. Lesbian, gay, bisexual, transgender, queer, and questioning (LG…

Thérapies de Conversion

Ramos, N., Burgess, A., & Ollen, E. (2023). The Current Status of Sociopolitical and Legal Issues Faced by Lesbian, Gay, Bisexual, Transgender, Queer, and Questioning Youth.. Adolesc Psychiatry (Hilversum), 12(3), 180-195. https://doi.org/10.2174/2210676611666211105120645

01/01/2023 Lire →

Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.

INTRODUCTION: Patients with intermediate or locally advanced hepatocellular carcinoma (HCC) who are not eligible for radical treatment typically have a poor overall prognosis. Treatment strategies tha…

Thérapies de Conversion

Wang, L., Wang, H., Cui, Y., Liu, M., Jin, K., Xu, D., Wang, K., & Xing, B. (2023). Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.. Front Oncol, 13, 1115109. https://doi.org/10.3389/fonc.2023.1115109

01/01/2023 Lire →

The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. In China, most HCC patients are diagnosed with advanced disease and in these cases surgery is challeng…

Thérapies de Conversion

Bai, J., Huang, M., Song, B., Luo, W., & Ding, R. (2023). The Current Status and Future Prospects for Conversion Therapy in the Treatment of Hepatocellular Carcinoma.. Technol Cancer Res Treat, 22, 15330338231159718. https://doi.org/10.1177/15330338231159718

01/01/2023 Lire →